NEW YORK (GenomeWeb) – Luminex has completed its roughly $90 million acquisition of molecular diagnostics firm Nanosphere, the firm announced today.

Its tender offer of $1.70 per share for all of the shares of Nanosphere expired as of midnight on June 29. According to Luminex, as of the expiration of the tender offer, a total of 45,252,609 shares were validly tendered and not withdrawn, representing a total of nearly 86 percent of Nanosphere's outstanding shares.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.